A recent report published by Infinium Global Research on liver fibrosis drug market provides an in-depth analysis of segments and sub-segments in the global as well as regional liver fibrosis drug market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional liver fibrosis drug market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global liver fibrosis drug market. According to the report, the global liver fibrosis drug market is projected to grow at a CAGR of 10.7% over the forecast period of 2019-2025.

Market Insight

Liver fibrosis drugs are used when there is the formation of excessive amounts of scar tissue in the organ due to repetitive or long-lasting injury or inflammation. Various types of chronic liver disease eventually cause fibrosis. These drugs are applicable to treat biliary fibrosis, parasitic infection fibrosis, metabolic fibrosis alcoholic fibrosis, viral hepatitis fibrosis, intoxication fibrosis, cardiogenic fibrosis, and alcoholic fibrosis. Hospitals and clinics are major users of liver fibrosis drugs.

The rising prevalence of liver fibrosis and liver diseases drives the growth of the liver fibrosis drug market. There are around 2 million deaths per year worldwide. In addition, the factors such as increasing government funding for treatment of liver fibrosis and liver diseases, growing geriatric population and increasing health awareness contribute to the growth of the liver fibrosis drug market. As per the World Health Organization, the world’s population over 60 years will be 22%. The increasing consumption of alcohol and unhealthy diet habits increases the cases of liver fibrosis that boosts the demand for liver fibrosis market. On the other hand, strict government regulations for drug approval and the risk of side effects from the use of these drugs restrains the growth of the liver fibrosis drug market. Moreover, research and development to innovate new drugs create numerously opportunities for the liver fibrosis drug market.

North America holds a larger share in the global liver fibrosis drug market. North America has an increasing number of patients with liver fibrosis contributing to the growth of the liver fibrosis drug market. Asia-Pacific region is anticipated to grow in the liver fibrosis drug market. In the Asia-Pacific region, there will be 1.3 billion people age above 60 years by 2050.

Segment Covered

The report on global liver fibrosis drug market covers segments such as drug class, and distribution channel. On the basis of drug class, the sub-markets include interferon (IFN) therapy, nucleoside analog, maloti lipid, and other drug classes. On the basis of distribution channel, the sub-markets include hospital pharmacies, retail pharmacies, and online pharmacies.

Companies Profiled:

The report provides profiles of the companies in the market such as Dicerna Pharmaceuticals, Inc., Pharmaxis Limited, Celgene Corporation, Dynavax Technologies Corporation, Mirum Pharmaceuticals, Gilead Sciences, Inc., Merck & Co., Inc., Johnson and Johnson, Novartis AG, and Other companies.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of liver fibrosis drug market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.